Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Clinical trial NCT01203917 · COMPLETED

Trial details

NCT number: NCT01203917
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Start date: 2010-09-01
Primary completion: 2012-08-01
Enrollment: 1060

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.